1. Scrip
  2. >>Advanced Therapies
  3. >>Gene Therapies

Safety Concerns Hit Bluebird Sickle Cell Trial, Again

 
• By Alaric DeArment

The FDA placed a partial hold on its clinical program for lovo-cel due to an adolescent patient experiencing anemia 18 months after treatment, raising uncertainty over filing plans.

Sickle cell anemia, 3D illustration showing blood vessel with normal and deformated crescent-like red blood cells
The FDA placed a partial hold on bluebird bio's clinical program for lovo-cel in sickle cell disease • Source: Shutterstock

Days after presenting incremental data for its gene therapy lovotibeglogene autotemcel (lovo-cel) for sickle cell disease (SCD), bluebird bio has found itself hit with another potential safety problem, in the form of a partial hold from the US Food and Drug Administration due to an adolescent patient experiencing anemia. That, in turn, has created uncertainty about the company’s filing plans for the therapy.

The company said 20 December that the FDA had placed the partial hold for patients younger than 18, after an...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Gene Therapies

Spain’s SpliceBio Secures Sanofi and Roche Support In $135m Financing

 
• By Kevin Grogan

Series B cash will be used to advance its Stargardt disease gene therapy.

New Regenxbio DMD Data Support Gene Therapy Accelerated Approval

 
• By Joseph Haas

Regenxbio reported functional and biomarker data from an ongoing study of RGX-202, which it hopes to file for approval in Duchenne muscular dystrophy in 2026.

Bluebird, Private Equity Firms Look To Sweeten Buyout Deal

 
• By Alaric DeArment

Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

More from Advanced Therapies

ASCO: Kite’s Dual-Targeting CAR-Ts Could Mitigate Toxicity, Resistance

 
• By Alaric DeArment

Gilead’s Kite division presented Phase I data for its next-generation CAR-T therapy KITE-363 in patients with B-cell lymphomas.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

BREAKING NEWS: Sanofi Bets $9.5bn To Bag Blueprint

 
• By Kevin Grogan

Buy boosts the French major's immunology pipeline.